Effect of Chemotherapy on Prometastatic Extracellular Vesicles Warrants Further Research

Share this content:
Chemotherapy could prompt metastasis in some breast tumors, according to findings from animal studies.
Chemotherapy could prompt metastasis in some breast tumors, according to findings from animal studies.

Patients with breast cancer undergoing neoadjuvant chemotherapy may experience cellular responses to the treatment that promote the metastatic spread of the disease, according to the results of an animal study. 

Previous studies in mice have suggested that cytotoxic chemotherapy may have prometastatic effects. Specifically, tumors releases extracellular vesicles (EVs) that facilitate the metastasis of disease in distant organs; however, the effect of chemotherapy on these EVs is unknown.

In this study, the researchers used breast cancer models to look at 2 classes of cytotoxic drugs — taxanes and anthracyclines — and found that both elicited tumor-derived EVs with enhanced prometastatic capacity. These EVs were enriched for certain proteins including annexin A6 (ANXA6), a CA2+-binding membrane-associated protein that has been implicated in the regulation of cancer cell invasion.

Further experiments showed that genetic inactivation of Anxa6 blunted the prometastatic effects of these chemotherapy-elicited EVs, leading the researchers to conclude that “the significance of EV-associated ANXA6 for breast cancer metastasis may … merit further research.”

However, the researchers acknowledged that they did not study survival associated with the various treatments and, therefore, they could not conclude whether “increased metastatic seeding and outgrowth in response to chemotherapy-elicited EVs would translate into shorter survival” across their disease models. 

“The potential participation of tumor-derived EVs in the process of human breast cancer metastasis is poorly understood at present and may be challenging to explore given the lack of validated breast-cancer-specific EV markers,” they wrote. “In the future, chemotherapy-elicited EVs might provide biomarkers for predicting metastasis risk associated with neoadjuvant chemotherapy in patients who do not achieve a complete response.”


  1. Keklikoglou I, Cianciaruso C, Güç E, et al. Chemotherapy elicits prometastatic extracellular vesicles in breast cancer models [published online December 31, 2018]. Nat Cell Biol. doi: 10.1038/s41556-018-0256-3

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs